These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 36813538)

  • 21. Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice.
    Huss V; Bower H; Wadström H; Frisell T; Askling J;
    Rheumatology (Oxford); 2022 May; 61(5):1810-1818. PubMed ID: 34324640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Bhushan V; Lester S; Briggs L; Hijjawi R; Shanahan EM; Pontifex E; Ninan J; Hill C; Cai F; Walker J; Goldblatt F; Wechalekar MD
    Front Med (Lausanne); 2021; 8():708168. PubMed ID: 34646840
    [No Abstract]   [Full Text] [Related]  

  • 23. Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis.
    Yiu ZZN; Becher G; Kirby B; Laws P; Reynolds NJ; Smith CH; Warren RB; Griffiths CEM;
    JAMA Dermatol; 2022 Oct; 158(10):1131-1141. PubMed ID: 35791876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time until onset of action when treating psoriatic arthritis: meta-analysis and novel approach of generating confidence intervals.
    Pham PA; Dressler C; Eisert L; Nast A; Werner RN
    Rheumatol Int; 2019 Apr; 39(4):605-618. PubMed ID: 30684041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE).
    Iannone F; Santo L; Bucci R; Semeraro A; Carlino G; Paoletti F; Quarta L; Leucci P; Zuccaro C; Marsico A; Scioscia C; D'Onofrio F; Mazzotta D; Muratore M; Cantatore FP; Lapadula G
    Clin Rheumatol; 2018 Mar; 37(3):667-675. PubMed ID: 29411182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.
    Elyoussfi S; Thomas BJ; Ciurtin C
    Rheumatol Int; 2016 May; 36(5):603-12. PubMed ID: 26892034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An overview of biologic disease-modifying antirheumatic drugs in axial spondyloarthritis and psoriatic arthritis.
    So A; Inman RD
    Best Pract Res Clin Rheumatol; 2018 Jun; 32(3):453-471. PubMed ID: 31171315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review.
    Emery P; Pope JE; Kruger K; Lippe R; DeMasi R; Lula S; Kola B
    Adv Ther; 2018 Oct; 35(10):1535-1563. PubMed ID: 30128641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient groups in Rheumatoid arthritis identified by deep learning respond differently to biologic or targeted synthetic DMARDs.
    Kalweit M; Burden AM; Boedecker J; Hügle T; Burkard T
    PLoS Comput Biol; 2023 Jun; 19(6):e1011073. PubMed ID: 37267387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden.
    Sigurdardottir V; Engstrom A; Berling P; Olofsson T; Oldsberg L; Sadler S; Parra-Padilla D; Melis L; Willems D
    J Med Econ; 2023; 26(1):1190-1200. PubMed ID: 37712618
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pattern of drug use in patients with psoriatic arthritis in Italy: study in a real-world setting.
    Perrone V; Losi S; Filippi E; Sangiorgi D; Degli Esposti L
    Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):721-727. PubMed ID: 33472454
    [No Abstract]   [Full Text] [Related]  

  • 33. Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study.
    Lund Hansen R; Schoedt Jørgensen T; Dreyer L; Hetland ML; Glintborg B; Askling J; Di Giuseppe D; Jacobsson LTH; Wallman JK; Nordstrom D; Aaltonen K; Kristianslund EK; Kvien TK; Provan SA; Gudbjornsson B; Love TJ; Kristensen LE
    Rheumatology (Oxford); 2021 Jan; 60(1):140-146. PubMed ID: 32591790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switching related to inefficacy in biologics and targeted synthetic therapies for psoriatic arthritis: a comparative real-life study.
    Freites-Nuñez D; Leon L; Toledano E; Candelas G; Martinez C; Rodriguez-Laguna M; Rubio D; Fernandez-Gutierrez B; Abasolo L
    Ther Adv Musculoskelet Dis; 2024; 16():1759720X241273083. PubMed ID: 39219744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis.
    Lindström U; Glintborg B; Di Giuseppe D; Schjødt Jørgensen T; Gudbjornsson B; Lederballe Grøn K; Aarrestad Provan S; Michelsen B; Lund Hetland M; Wallman JK; Nordström D; Trokovic N; Love TJ; Krogh NS; Askling J; Jacobsson LTH; Kristensen LE
    Rheumatology (Oxford); 2021 Aug; 60(8):3635-3645. PubMed ID: 33367900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in elderly patients with rheumatoid arthritis: real-world data from the KOBIO Registry.
    Koh JH; Lee SK; Kim J; Kim HA; Shin K; Min JK
    Clin Exp Rheumatol; 2021; 39(2):269-278. PubMed ID: 32324126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
    Shepherd J; Cooper K; Harris P; Picot J; Rose M
    Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
    Bonafede M; Joseph GJ; Princic N; Harrison DJ
    J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration.
    Michelsen B; Lindström U; Codreanu C; Ciurea A; Zavada J; Loft AG; Pombo-Suarez M; Onen F; Kvien TK; Rotar Z; Santos MJ; Iannone F; Hokkanen AM; Gudbjornsson B; Askling J; Ionescu R; Nissen MJ; Pavelka K; Sanchez-Piedra C; Akar S; Sexton J; Tomsic M; Santos H; Sebastiani M; Österlund J; Geirsson AJ; Macfarlane G; van der Horst-Bruinsma I; Georgiadis S; Brahe CH; Ørnbjerg LM; Hetland ML; Østergaard M
    RMD Open; 2020 Sep; 6(3):. PubMed ID: 32950963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Canadian Adalimumab Postmarketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (COMPLETE-PsA): 12-month Results of Comparative Effectiveness of Adalimumab and nbDMARDs.
    Khraishi MM; Remple VP; Silverberg S; Stewart JC; Florica B; Bessette L
    J Rheumatol; 2022 May; 49(5):454-464. PubMed ID: 35033999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.